Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled date : 2022 - 10 - 27 save search
Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat
Published: 2022-10-27 (Crawled : 23:00) - biospace.com/
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: -0.94%
H: 1.9%
C: -0.95%
rubraca trial cancer prostate cancer
Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
Published: 2022-10-27 (Crawled : 22:00) - biospace.com/
EWTX | $15.23 -1.42% -1.44% 540K
|
Manufacturing
|
| O: 1.21%
H: 0.0%
C: -6.88%
edg-5506 treatment trial therapeutics duchenne
Omega Therapeutics Announces First Patient Dosed in Landmark MYCHELANGELO™ I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC Oncogene
Published: 2022-10-27 (Crawled : 18:00) - biospace.com/
OMGA | $2.4 -0.83% -0.83% 400K
|
|
| O: 2.16%
H: 5.56%
C: -7.05%
otx-2002 trial therapeutics
GSK Pulls Plug on Investigational RA Drug Following Trial Failure
Published: 2022-10-27 (Crawled : 16:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: 0.0%
drug trial
Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
Published: 2022-10-27 (Crawled : 13:00) - globenewswire.com
DYAI A | $1.61 1.26% 1.24% 14K
|
Health Technology
|
| O: 4.65%
H: 0.44%
C: -1.78%
dyai-100 covid-19 candidate vaccine trial approval
REGENXBIO to Host Conference Call on November 3 to Discuss Third Quarter 2022 Financial Results, Recent Operational Highlights and Interim Data from Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy
Published: 2022-10-27 (Crawled : 12:20) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 1.18%
H: 1.81%
C: -2.24%
rgx-314 altitude treatment conference trial financial diabetic
Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia
Published: 2022-10-27 (Crawled : 12:00) - globenewswire.com
MBIO | $0.3451 -6.98% -7.51% 130K
|
Health Technology
|
| O: -1.51%
H: 11.3%
C: 6.78%
FBIO | $1.765 -2.49% -2.55% 190K
|
Health Technology
|
| O: 3.55%
H: 0.0%
C: -1.58%
mb-106 trial international
HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
Published: 2022-10-27 (Crawled : 12:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: -2.74%
H: 5.16%
C: 1.53%
renal trial china cell carcinoma
Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial
Published: 2022-10-27 (Crawled : 12:00) - globenewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: 1.02%
H: 0.0%
C: -3.53%
alent-101 leukemia trial
Trevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting
Published: 2022-10-27 (Crawled : 12:00) - prnewswire.com
TRVI | $2.82 5.03% 4.79% 140K
|
Health Technology
|
| O: 1.02%
H: 2.01%
C: -2.01%
meeting trial therapeutics phase 2
MIRAGE Phase III Randomized Controlled Trial Demonstrates Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
Published: 2022-10-27 (Crawled : 11:00) - prnewswire.com
VRAY | $0.025 -39.9% -61.87% 110M
|
Health Technology
|
| O: 2.34%
H: 0.23%
C: -4.79%
mridian trial cancer prostate cancer
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
Published: 2022-10-27 (Crawled : 11:00) - biospace.com/
PBYI | $5.01 0.4% 0.4% 290K
|
Health Technology
|
| O: 1.32%
H: 0.43%
C: -3.46%
symposium trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.